HerediGENE®

HerediGENE® is a diagnostic multi-gene test for hereditary cancer, which analyses 52 genes, including BRCA 1/2 , which are involved in the increased risk of breast, ovarian, prostate, colorectal and other hereditary cancers.

This test can be used as a tool for prevention. People who will be diagnosed with a pathogenic mutation can perform prophylactic surgery and pharmacotherapy, dramatically reducing the likelihood of developing this cancer.
It offers information to the doctor about personalized surgical and pharmaceutical treatment for their patients.
Finally, it can be used to identify family members at risk of cancer.

Who should have the gene test for hereditary cancer

All individuals with breast cancer according to global guidelines (American Society of Breast Surgeons)
Individuals with any type of cancer at an early age
Individuals with bilateral breast and/or ovarian cancer
Individuals with the same type of cancer occurring in close relatives and cancer incidence in multiple generations of a family
Individuals with rare tumors at any age
Individuals with first-degree relatives who have had cancer at an early age or have a known gene mutation.
Individuals who develop hundreds or thousands of polyps
Men with breast cancer

Cancer Types
Breast, Colorectal, Prostate, Pancreatic, Ovarian, Gastric, Melanoma, Thyroid, Kidney, Endometrial

Cancer Syndromes
Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome, Cowden Syndrome, Li-Fraumeni Syndrome, Peutz-Jeghers Syndrome, Familial Adenomatous Polyposis, Von-Hippel Lindau Syndrome, Multiple Endocrine Neoplasia, Other.

Test Specifications

A person with an inherited pathogenic mutation is at increased risk for developing certain type of cancer. Therefore, the gene profile offers important information for the treatment of patients and the management of themselves and their families.

The HerediGENE® analyzes 52 genes,which are involved in the cancer susceptibility, 21 of which are related to Homologous Recombination (HR).

This test helps phycisians choose the best surgical and pharmaceutical plan for their patients.
It identifies which family members are at increased risk of developing cancer.
Also, it determines the individuals who do not carry a pathogenic mutation and relieves them of the stress of the occurrence of hereditary cancer.

Why HerediGENE

The HerediGENE® test is designed to ensure maximum sensitivity and accuracy. Advanced Next Generation Sequencing Technology (NGS) is used and all findings are classified using the most reliable, updated databases from our Bioinformatics department.
Many genes are analyzed simultaneously using just a small amount of blood or saliva in a very short time and at a low cost.
Continuous support is provided to the physician and the patient by our experienced scientific team
In addition to the above, free Genetic Counselling is provided. Detailed family medical history and genetic counselling before, during and after the examination.

The HerediGENE® test analyses the following genes:

Colon	Breast	Pancreas	Ovarian	Gastric	Melanoma	Endometrial	Endocrine	Prostate	HRD	Associated Syndrome
APC		APC		APC			APC			Familial Adenomatous Polyposis
	ATM	ATM	ATM					ATM	ATM	Ataxia Telangilectasia (recessive)
AXIN2										Polyposis/Oligodontia
	BARD1		BARD1						BARD1
BMPR1A				BMPR1A						Juvenile Polyposis Sydrome
	BRCA1	BRCA1	BRCA1		BRCA1			BRCA1	BRCA1	Hereditary Breast and Ovarian Cancer
	BRCA2	BRCA2	BRCA2		BRCA2			BRCA2	BRCA2	Hereditary Breast and Ovarian Cancer, Fanconi anaemia FA-D1 (recessive)
	BRIP1		BRIP1						BRIP1	Fanconi anaemia FA-J (recessive)
	CDH1			CDH1						Hereditary diffuse gastric cancer
					CDK4
		CDKN2A			CDKN2A					Familial Atypical Mole-Malignant Melanoma Syndrome (FAMMM)
CHEK2	CHEK2							CHEK2	CHEK2
EPCAM		EPCAM	EPCAM			EPCAM				Lynch Syndrome
									FANCA	Fanconi anaemia FA-A (recessive)
									FANCL	Fanconi anaemia FA-L (recessive)
									FANCM	Fanconi anaemia FA-M (recessive)
								HOXB13
							MEN1			Multiple endocrine neoplasia Type1
MLH1		MLH1	MLH1			MLH1		MLH1		Lynch Syndrome / Constitutional mismatch repair deficiency (CMMRD) syndrome (recessive)
									MRE11	Ataxia-telanglectasia-like disorder (recessive)
MSH2		MSH2	MSH2			MSH2		MSH2		Lynch Syndrome
MSH3										Adenomatous Polyposis (recessive)
MSH6		MSH6				MSH6		MSH6		Lynch Syndrome
MUTYH										MUTYH-associated polyposis
	NBN								NBN	Nijmegen breakage syndrome (recessive)
	NF1	NF1		NF1			NF1			Neurofibromatosis Type1
NTHL1										Adenomatous Polyposis (recessive
	PALB2	PALB2	PALB2					PALB2	PALB2	Fanconi anaemia FA-N (recessive)
PMS2						PMS2		PMS2		Lynch Syndrome
POLE										Adenomatous Polyposis
POLD1										Adenomatous Polyposis
									PPP2R2A
PTEN	PTEN				PTEN	PTEN	PTEN			Cowden
	RAD50								RAD50	Nijmegen breakage syndrome like disorder (recessive)
									RAD51B
	RAD51C		RAD51C						RAD51C	Fanconi anaemia FA-O (recessive)
	RAD51D		RAD51D						RAD51D	Fanconi anaemia (recessive)
							RET			Multiple endocrine neoplasia Type2
SMAD4				SMAD4						Juvenile Polyposis / Hereditary hemorhagic telanglectasia (HHT)
			SMARCA4							AD small cell carcinoma of the ovary hypercalcemic type (SCCOTH), AD rhabdoid tumor predisposed lion syndrome type 2 (RTPS2)
STK11	STK11	STK11	STK11	STK11		STK11				Peutz-Jeghers Sydrome
TP53	TP53	TP53		TP53	TP53					Li-Fraumeni Sydrome
							VHL			von Hippel-Lindau Sydrome

Frequently Asked Questions

What types of cancer does it cover?

The examination mainly covers the occurrence of breast and ovarian, prostate, colorectal, pancreatic, kidney, gastric, thyroid and melanoma cancers.

Are BRCA genes included?

Yes, BRCA (BRCA1 & BRCA2) genes are included in addition to 50 more genes shown in the panel.

If a pathogenic mutation is found, should all family members be tested?

The results obtained by the test are useful for the entire family, as it is enough for a person to inherit a mutation from one parent, to be at increased risk of developing cancer. All in all, a child whose parent is a mutant carrier has a 50% chance of inheriting the mutation. More distant relatives are also at risk of carrying the mutation. Given these facts, individuals who may be carriers of inherited gene mutation can be identified by referral for genetic testing. Note that hereditary cancer susceptibility syndromes can be associated with many different types of cancer. Therefore, a mutation detected in the sample for breast or ovarian cancer may be associated with an increased risk of pancreatic or prostate cancer.

In how many days will the results be available?

Results will be available in 20 business days.

What type of sample is required for the test?

Whole peripheral blood in EDTA vials (2 vials) or saliva in a special kit supplied by our company.

Is blood sampling performed at the Genekor facility?

No, the company does not perform blood samplings, so you should contact us at 210-6032138 and we will guide you.

Is the test covered by any public/private insurance?

For cost coverage, please contact the secretariat here.

Following the launch of e-prescribing for BRCA (BRCA1 & BRCA2) gene mutation testing for hereditary breast and ovarian cancer, please find below the Electronic Prescription Template with the relevant detailed e-prescribing instructions for BRCA 1,2 genes for the 4 different cases.

Case 1: Women diagnosed with Ca breast before the age of 45
Case 2: Women diagnosed with Breast Ca at age greater than or equal to 45 years with Family History
Case 3: Women diagnosed with malignant epithelial neoplasm of the ovary
Case 4: Women with a known BRCA (BRCA1 & BRCA2) mutation in the family

How do I make the payment for the test?

Payment can be made by bank transfer or debit/credit card

How I send the sample and receive the results?

Regarding the receipt of the sample, please contact the secretariat. The results are shared with your doctor and with you via email.

How to order the test?

Our Customer Service Team is committed to answer your questions with regards to the services offered by Genekor. If you would like to order any of the tests that Genekor performs please contact us directly.

*To complete the test, you are required to complete and send the Consent form that you will find on the link below.

CONSENT FORM